AstraZeneca scores an unexpected win. Photograph by Andrew Yates AFP—Getty Images

Why Drug Giant AstraZeneca’s Stock Soared More Than 9% on Friday

May 12, 2017

Shares of U.K.-based pharma giant AstraZeneca—an $80 billion-plus company by market value—skyrocketed more than 9% in Friday trading following unexpectedly impressive and early clinical trial results for a key drug in lung cancer patients.

The treatment, durvalumab (sold under the brand name Imfinzi), is part of a lucrative new class of cancer immunotherapy drugs called "checkpoint inhibitors" being chased by drug titans like Merck, Bristol-Myers Squibb, Pfizer, and Roche. AstraZeneca was considerably behind all of those other companies in getting its drug FDA-approved; but the new trial results could give it a big advantage.

Click here to subscribe to Brainstorm Health Daily, our brand new newsletter about health innovations.

"These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option," said Sean Bohen, an AstraZeneca executive vice president, in a statement.

Wall Street echoed the optimism. "In theory, this could open a market opportunity of $1.75 billion to $3.5 billion (or more) for the drug, which is not included in our current forecasts," wrote Deutsche Bank analysts in a research note.

The cancer immunotherapy field (comprised of therapies that use the body's immune system to fight the disease) has been a roller coaster over the last few years. Bristol-Myers once seemed like it could dominate the space before big clinical trial setbacks for its treatment, Opdivo; Merck's Keytruda has been on a roll, including a key FDA approval this week for treating advanced lung cancer.

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions